Orris

Ectopic pregnancy long question MMR Jsssy STI TREATMENT Precious puberty

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Here are comprehensive long-question answers for all five topics:

1. ECTOPIC PREGNANCY

Definition

An ectopic pregnancy is one in which implantation occurs outside the uterine cavity. The fallopian tube accounts for ~95% of cases (ampulla most common). Other sites include the cervix, ovary, abdominal cavity, and interstitial portion of the tube. It is the most common obstetric cause of maternal death in the first trimester.
  • Roberts and Hedges' Clinical Procedures in Emergency Medicine

Incidence

Estimated at 0.64% to 2.0% of all pregnancies. In 50% of cases, patients received at least two medical evaluations before the correct diagnosis was made.

Risk Factors

  • History of salpingitis / pelvic inflammatory disease (PID)
  • Intrauterine contraceptive device (IUD) use
  • Previous tubal ligation
  • Prior ectopic pregnancy
  • Tubal surgery
  • Assisted reproductive technology (ART)
  • Smoking

Pathophysiology

Any factor delaying or preventing transport of the fertilized ovum through the fallopian tube leads to ectopic implantation. The trophoblast invades the thin tubal wall, eventually eroding blood vessels and causing tubal rupture and hemorrhage.

Clinical Features (Classic Triad)

  1. Amenorrhea (missed period - though ~50% of patients report a normal menstrual history)
  2. Pelvic/abdominal pain - most consistent finding; may be unilateral, colicky, or referred to the shoulder (diaphragmatic irritation from hemoperitoneum)
  3. Vaginal bleeding - usually abnormal, dark spotting
Additional features:
  • Cervical motion tenderness (chandelier sign)
  • Adnexal mass/tenderness
  • Syncope or collapse (if ruptured)
  • Decidual cast passed vaginally (virtually pathognomonic when combined with a positive pregnancy test)
  • Shoulder tip pain (diaphragmatic irritation from blood)
  • Note: Blood in the peritoneal cavity does NOT consistently correlate with peritoneal irritation, blood pressure, or pulse rate. Bradycardia may occur with significant hemoperitoneum.

Signs of Rupture

  • Severe sudden pain
  • Hemodynamic instability (tachycardia, hypotension, collapse)
  • Drop in hematocrit
  • Peritoneal signs (rebound tenderness, guarding)

Investigations

Pregnancy Test

  • Urine beta-hCG: sensitive at 20 mIU/mL; positive in 98% of cases. A negative urine beta-hCG rules out pregnancy in >98% of cases.
  • Serum beta-hCG: sensitive to 5 mIU/mL.
  • In a normal intrauterine pregnancy, serum beta-hCG should double approximately every 48 hours in the first trimester. Slow rise (or plateau) is suspicious for ectopic or nonviable pregnancy.

Discriminatory Zone

  • Transvaginal ultrasound (TVUS): intrauterine gestational sac should be visible when beta-hCG is 1200-2000 mIU/mL
  • Transabdominal ultrasound: visible when beta-hCG is >6000 mIU/mL
  • If no intrauterine pregnancy is seen on US and beta-hCG exceeds the discriminatory zone: 86-100% chance of ectopic pregnancy

Ultrasound Findings

  • Empty uterus with positive beta-hCG = strongly suspicious
  • Adnexal mass separate from the ovary
  • Free fluid in the pouch of Douglas (hemoperitoneum)
  • Pseudogestational sac (decidual reaction in uterus - do NOT mistake for IUP)

Culdocentesis

  • Aspiration of the pouch of Douglas via posterior vaginal fornix
  • Accuracy: 85-95%
  • Positive = non-clotting blood with hematocrit >15% = hemoperitoneum
  • Positive pregnancy test + positive culdocentesis = ectopic pregnancy in 99% of cases
  • Negative result does not rule out early ectopic pregnancy

Other Tests

  • CBC (anemia, leukocytosis)
  • Blood group and cross-match
  • Progesterone levels (low in non-viable pregnancy)
  • Laparoscopy - gold standard for diagnosis and treatment

Management

Expectant Management

  • Suitable when beta-hCG is falling spontaneously
  • Ratios: beta-hCG at 48 hours vs. initial <0.87 is predictive of spontaneous resolution
  • Requires close follow-up

Medical Management - Methotrexate

Methotrexate (MTX), a folate antagonist, inhibits rapidly dividing trophoblast cells.
Absolute Contraindications:
  • Intrauterine pregnancy
  • Hemodynamically unstable patient
  • Ruptured ectopic pregnancy
  • Breastfeeding, immunodeficiency
  • Moderate to severe anemia, leukopenia, thrombocytopenia
  • Active pulmonary disease / peptic ulcer disease
  • Clinically significant hepatic or renal dysfunction
Relative Contraindications:
  • Ectopic >4 cm on TVUS
  • Embryonic cardiac motion on TVUS
  • Beta-hCG >5,000 mIU/mL
  • Unable to comply with follow-up
Dosing Regimens:
RegimenProtocol
Single-doseMTX 50 mg/m² IM on Day 0; check beta-hCG on Days 4 & 7; if <15% fall, repeat dose
Two-doseMTX 50 mg/m² on Day 0 and Day 4; check beta-hCG on Day 7
MultidoseMTX 1 mg/kg IM alternating with leucovorin 0.1 mg/kg on Days 1, 3, 5, 7
  • Success rate: ~70-95% (single dose ~90%)
  • A second dose is needed in up to 25% of women
Side Effects: Nausea, vomiting, stomatitis, abdominal pain (most common); bone marrow suppression, alopecia, elevated LFTs, pneumonitis (less common)
  • Advise patient to avoid alcohol, NSAIDs, folic acid supplements, and sexual intercourse during treatment
  • Avoid sunlight exposure (photosensitivity)
Pre-treatment workup: CBC, blood type, LFTs, electrolytes, creatinine

Surgical Management

Indicated when:
  • Patient is hemodynamically unstable (ruptured ectopic - EMERGENCY)
  • Contraindication to MTX exists
  • Failed medical management
  • Patient preference
Laparoscopy vs. Laparotomy:
  • Laparoscopy is superior in most cases: shorter hospital stay, shorter operative time, shorter convalescence, less blood loss, fewer adhesions, similar reproductive outcomes
  • Laparotomy is indicated for: hemodynamic instability, abdominal pregnancy, extensive adhesive disease, lack of laparoscopic equipment/skill
Procedures:
  • Salpingostomy (linear incision, pregnancy removed, tube preserved) - preferred if patient desires future fertility
  • Salpingectomy (tube removal) - for patients not desiring future fertility, or if tube is damaged beyond repair. Also preferred if contralateral tube is healthy (reduces risk of persistent ectopic)
Reproductive Outcomes:
  • Subsequent ectopic pregnancy risk: ~10% after either MTX or salpingostomy
  • Tubal patency: >80% after either treatment
  • Subsequent intrauterine pregnancy: 36-64% (similar for both methods)
  • Berek & Novak's Gynecology

Rhesus (Rh) Isoimmunization

All Rh-negative women with ectopic pregnancy should receive anti-D immunoglobulin to prevent isoimmunization.

2. MATERNAL MORTALITY RATIO (MMR)

Definitions

Park's Textbook of Preventive and Social Medicine; Harrison's Principles of Internal Medicine 22E

Maternal Death (WHO Definition)

"The death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of pregnancy, from any cause related to or aggravated by the pregnancy or its management but NOT from unintentional or incidental causes."

Types of Maternal Deaths

Direct Obstetric Deaths: Deaths resulting from obstetric complications of the pregnant state (pregnancy, labour, puerperium), or from interventions, omissions, or incorrect treatment. Examples:
  • Obstetric hemorrhage (PPH, APH)
  • Hypertensive disorders (eclampsia, HELLP)
  • Puerperal sepsis
  • Complications of anaesthesia/caesarean section
Indirect Obstetric Deaths: Deaths from pre-existing disease or disease that developed during pregnancy and was not due to direct obstetric causes, but was aggravated by physiological effects of pregnancy. Examples:
  • Cardiac disease aggravated by pregnancy
  • Renal disease aggravated by pregnancy
  • In the US (2014-2017): cardiovascular disease (including cardiomyopathy) accounted for nearly 1/3 of pregnancy-related deaths
Late Maternal Death: Death of a woman from direct or indirect obstetric causes, after more than 42 days but less than one year after termination of pregnancy (ICD-10 codes: O96, O97)
Pregnancy-Related Death: Death of a woman while pregnant or within 42 days, irrespective of cause (includes accidental/incidental causes). Broader than maternal death.

Calculation

Maternal Mortality Ratio (MMR)

$$MMR = \frac{\text{No. of maternal deaths in a year}}{\text{No. of live births in same year}} \times 100{,}000$$
This quantifies the risk of maternal death relative to the number of live births.

Maternal Mortality Rate (MMRate)

$$MMRate = \frac{\text{No. of maternal deaths}}{\text{Person-years lived by women of reproductive age}} $$
Captures both risk per pregnancy AND the level of fertility in the population.

Proportion of Maternal Deaths (PM)

Number of maternal deaths / Total deaths among women aged 15-49 years

Adult Lifetime Risk of Maternal Death

Probability that a 15-year-old girl will eventually die from a maternal cause.

Global MMR Categories

CategoryMMR (per 100,000 live births)
High300-499
Very High500-999
Extremely High≥1000

Global Statistics (2017 WHO Estimates)

  • Global MMR: 211 per 100,000 live births (295,000 total maternal deaths)
  • Global lifetime risk: 1 in 190
  • Sub-Saharan Africa MMR: 542 (lifetime risk 1 in 37) - only region with "very high" MMR
  • Extremely high MMR countries: South Sudan (1150), Chad (1140), Sierra Leone (1120)
  • Highest absolute numbers: Nigeria (67,000 deaths) and India (35,000 deaths) = ~35% of global maternal deaths
  • Europe MMR: ~10 | Australia/New Zealand: ~7
  • US MMR (2021): 32.9 per 100,000 births; with significant racial disparity (Black women: 69.9 vs. White women: 26.6)

Leading Causes of Maternal Mortality

In resource-poor countries:
  1. Obstetric hemorrhage (PPH most important)
  2. Hypertensive disorders (eclampsia)
  3. Sepsis/infection
  4. Obstructed labor
  5. Complications of unsafe abortion
In resource-rich countries:
  1. Cardiovascular disease/cardiomyopathy (~33%)
  2. Infection/sepsis
  3. Hemorrhage
  4. Thromboembolism
  5. Hypertensive disorders

Timing of Maternal Deaths

  • 50-70% occur in the postpartum period
  • 45% of postpartum deaths occur within the first 24 hours after delivery
  • >2/3 occur within the first week
  • 11-17% occur during childbirth itself
  • In the US, 1 in 3 pregnancy-related deaths occur 1 week to 1 year after delivery

Methods of Measuring MMR

  1. Civil registration systems (ideal)
  2. Household surveys
  3. Sisterhood methods
  4. RAMOS (Reproductive-age mortality studies)
  5. Verbal autopsy
  6. Census

Key Interventions to Reduce MMR

  1. Access to contraceptive services (birth spacing)
  2. Access to safe pregnancy termination
  3. Skilled birth attendants at all deliveries
  4. Access to emergency obstetric care and cesarean delivery
  5. Antenatal, natal, and postnatal care
  6. Empowerment of women and female literacy

3. "JSSY" - NOTE

The abbreviation "Jssy" in your query is unclear. This likely refers to one of:
  • Jessie's Rule - not a recognized standard medical eponym
  • JSSY may be a local/institutional abbreviation for a specific topic in your curriculum
Based on common OBG/GYN exam topics near "ectopic pregnancy," this may refer to Jain's criteria or possibly it was meant as a shorthand for a specific rule. If this refers to a specific rule taught in your institution, please clarify. Below are the two most likely candidates:
If it refers to "Sensitivity/Specificity of USS in ectopic pregnancy" - the discriminatory zone and the combined beta-hCG + USS approach described above under Ectopic Pregnancy applies.
If it refers to scoring systems for ectopic: The ADNEXAL scoring or EP-SQ scoring systems are used in some centers to risk-stratify women for expectant vs. medical vs. surgical management.
Please clarify what "Jsssy/JSSY" refers to in your course, and a detailed answer will be provided.

4. STI (SEXUALLY TRANSMITTED INFECTION) TREATMENT

Goldman-Cecil Medicine; Katzung's Basic and Clinical Pharmacology

A. Chlamydia (Chlamydia trachomatis)

Recommended Treatment (CDC - Nonpregnant):
  • Doxycycline 100 mg orally twice daily for 7 days (FIRST LINE - ~5% better cure rate than azithromycin)
Alternative:
  • Azithromycin 1g orally single dose (preferred if adherence is a concern; ~5% lower cure rate for urogenital chlamydia)
  • Levofloxacin 500 mg orally once daily for 7 days
In Pregnancy:
  • Azithromycin 1g single dose (safe in pregnancy; doxycycline is contraindicated)
Rectal Chlamydia:
  • Doxycycline 100 mg twice daily for 7 days (significantly more efficacious than azithromycin for rectal infection)
Chlamydial PID:
  • Doxycycline 100 mg twice daily for 14 days + Ceftriaxone 500 mg IM single dose + Metronidazole 500 mg twice daily for 14 days (to cover gonorrhea and anaerobes)
Epididymitis (Chlamydial):
  • Doxycycline 100 mg twice daily for 10 days
Lymphogranuloma Venereum (LGV):
  • Doxycycline 100 mg twice daily for 3 weeks
  • Alternative: Azithromycin 1g weekly for 3 weeks
Neonatal Chlamydia:
  • Erythromycin base 50 mg/kg/day orally in 4 divided doses for 14 days

B. Gonorrhea (Neisseria gonorrhoeae)

Uncomplicated Urogenital/Rectal/Pharyngeal:
  • Ceftriaxone 500 mg IM single dose (preferred; if pharyngeal: 1g)
  • If co-infection with chlamydia suspected: add Doxycycline 100 mg twice daily for 7 days
Alternative (if ceftriaxone not available):
  • Gentamicin 240 mg IM + Azithromycin 2g orally (single dose)
Disseminated Gonococcal Infection (DGI):
  • Ceftriaxone 1g IV/IM every 24 hours for 7 days
Gonorrheal Conjunctivitis (Ophthalmia neonatorum):
  • Ceftriaxone 25-50 mg/kg IV/IM single dose (prophylaxis: 1% silver nitrate or erythromycin ointment)

C. Syphilis (Treponema pallidum)

StageTreatment
Primary, Secondary, Early Latent (<1yr)Benzathine Penicillin G 2.4 million units IM single dose
Late Latent (>1yr) or Unknown DurationBenzathine Penicillin G 2.4 million units IM weekly x 3 doses
Tertiary (Gummatous, Cardiovascular)Benzathine Penicillin G 2.4 million units IM weekly x 3 doses
NeurosyphilisAqueous Crystalline Penicillin G 18-24 million units/day IV for 10-14 days
In PregnancyPenicillin (same regimen by stage; penicillin-allergic patients must be desensitized)
Penicillin Allergy (nonpregnant)Doxycycline 100 mg orally twice daily x 14 days (primary/secondary)
Jarisch-Herxheimer Reaction: Fever, rigors, headache within 24 hours of first treatment dose in early syphilis - managed with NSAIDs/paracetamol.

D. Trichomoniasis (Trichomonas vaginalis)

  • Metronidazole 2g orally single dose (preferred)
  • Alternative: Metronidazole 500 mg twice daily for 7 days
  • Tinidazole 2g orally single dose (alternative; fewer GI side effects)
  • Treat sexual partners simultaneously
  • Avoid alcohol during and 24 hours (48 hours for tinidazole) after treatment

E. Bacterial Vaginosis

  • Metronidazole 500 mg orally twice daily for 7 days (preferred)
  • Metronidazole gel 0.75% intravaginally once daily for 5 days
  • Clindamycin 300 mg orally twice daily for 7 days

F. Genital Herpes (HSV)

First Episode:
  • Acyclovir 400 mg orally three times daily for 7-10 days
  • OR Valacyclovir 1g twice daily for 7-10 days
  • OR Famciclovir 250 mg three times daily for 7-10 days
Recurrent Episodes:
  • Acyclovir 400 mg three times daily for 5 days
  • OR Valacyclovir 500 mg twice daily for 3 days
Suppressive Therapy:
  • Acyclovir 400 mg twice daily (long-term)
  • OR Valacyclovir 500-1000 mg once daily

G. Human Papillomavirus (HPV) / Genital Warts

External Warts:
  • Patient-applied: Imiquimod 5% cream (3x/week, wash off after 6-10 hours) OR Podofilox 0.5% solution twice daily for 3 days
  • Provider-applied: Cryotherapy (liquid nitrogen), Trichloroacetic acid (TCA) 80-90%, Podophyllin resin 10-25%
  • Surgical: Surgical excision, laser ablation
Cervical Disease: Colposcopy + biopsy; treatment based on CIN grade
Prevention: HPV vaccination (9-valent preferred) - ages 11-12 years (up to 26 for all; up to 45 for shared decision-making)

H. Chancroid (Haemophilus ducreyi)

  • Azithromycin 1g orally single dose (preferred)
  • OR Ceftriaxone 250 mg IM single dose
  • OR Ciprofloxacin 500 mg twice daily for 3 days

I. General Principles for All STIs

  • Test and treat sexual partners (partner notification)
  • Test for co-infections (HIV, hepatitis B & C, syphilis)
  • Counsel on consistent condom use
  • Abstain from sexual intercourse until treatment completed and partners treated
  • Follow-up test of cure where indicated (especially in pregnancy)
  • Mandatory reporting of certain STIs (gonorrhea, syphilis, chlamydia, HIV)

5. PRECOCIOUS PUBERTY

Definition

Precocious puberty is the appearance of secondary sexual characteristics before:
  • Girls: age 8 years (some guidelines use age 7 for White girls, age 6 for Black girls)
  • Boys: age 9 years
Textbook of Family Medicine; Harrison's Principles of Internal Medicine 22E

Classification

1. Central (GnRH-Dependent) Precocious Puberty - CPP (True Precocious Puberty)

Due to early activation of the hypothalamic-pituitary-gonadal (HPG) axis with premature GnRH secretion.
  • Gonadotropin levels are ELEVATED (LH, FSH raised)
  • Pubertal progression follows normal sequence, just at an earlier age
Causes:
  • Idiopathic (most common cause in girls, ~90%)
  • CNS lesions: hypothalamic hamartoma (most common CNS cause), optic glioma, astrocytoma, ependymoma, arachnoid cysts, tuberous sclerosis, craniopharyngioma
  • Inflammatory/infectious lesions of CNS
  • After treatment of peripheral precocity (especially CAH)
  • Primary hypothyroidism (Van Wyk-Grumbach syndrome)
  • Mutations in kisspeptin (KISS1), kisspeptin receptor (KISS1R), and MKRN3 genes
Note: In boys, an underlying CNS lesion is NOT UNUSUAL and must be excluded by MRI.

2. Peripheral (GnRH-Independent) Precocious Puberty - PPP

Sex steroid secretion occurs independently of LH/FSH.
  • Gonadotropin levels are SUPPRESSED (LH, FSH low/prepubertal)
  • Also called "pseudo-precocious puberty"
Causes:
  • Congenital adrenal hyperplasia (CAH) - 21-hydroxylase deficiency most common
  • McCune-Albright syndrome (GNAS1 activating mutation) - polyostotic fibrous dysplasia, cafe-au-lait spots, autonomous gonadal activation
  • Activating LH receptor mutations - familial male-limited precocious puberty (testotoxicosis)
  • hCG-secreting tumors (germ cell tumors, hepatoblastoma)
  • Androgen-/estrogen-producing adrenal or gonadal tumors
  • Exogenous sex steroid exposure (estrogen creams, contaminated food)
  • Primary hypothyroidism

3. Incomplete/Benign Variants of Precocious Puberty

These are normal variants that do not require treatment in most cases:
  • Isolated premature thelarche - breast development without other signs; often resolves spontaneously especially in girls <2 years
  • Isolated premature pubarche/adrenarche - pubic hair development; usually self-limited; evaluate with ACTH stimulation to exclude late-onset CAH
  • Isolated premature menarche
  • Adolescent male gynecomastia - self-limited, mainly a social concern
  • >75% of children investigated for precocious puberty have benign diagnoses requiring no treatment

Classification by Direction

  • Isosexual precocity - sexual development consistent with the child's phenotypic sex (e.g., feminization of a female)
  • Heterosexual (contrasexual) precocity - virilization of a female or feminization of a male

Clinical Features

  • Development of secondary sexual characteristics ahead of age
  • Accelerated linear growth (tall in childhood but short in adulthood due to early epiphyseal closure)
  • Advanced bone age on wrist X-ray
  • Psychological impact (social and emotional difficulties)
  • Girls: breast development (thelarche), pubic hair (pubarche), menarche
  • Boys: testicular enlargement (>4 mL before age 9), penile growth, pubic hair, facial hair, voice change

Investigations

Initial

  1. Bone age (wrist X-ray) - advanced bone age in true precocity
  2. Serum LH, FSH - elevated in GnRH-dependent; suppressed in GnRH-independent
  3. Serum sex steroids (testosterone in boys, estradiol in girls)
  4. GnRH stimulation test - LH rises markedly in CPP; blunted in PPP

If CPP Confirmed

  • MRI brain (with gadolinium, focusing on hypothalamus/pituitary) - mandatory in boys; recommended in girls <6 years or with neurological signs

If PPP Suspected

  • DHEAS and 17-hydroxyprogesterone - elevated in CAH
  • Pelvic ultrasound (girls) - ovarian cysts, tumors
  • Testicular ultrasound (boys) - Leydig cell tumor
  • CT/MRI adrenal glands - adrenal tumor
  • Thyroid function tests (TSH)

Treatment

Central (GnRH-Dependent) Precocious Puberty

GnRH Analogues (GnRH agonists) - treatment of choice
  • Examples: Leuprolide acetate, triptorelin, histrelin implant
  • Mechanism: Down-regulate pituitary GnRH receptors when given continuously (opposite of pulsatile GnRH which stimulates) - reversibly suppresses LH, FSH, and sex steroids
  • Benefits: Suppress secondary sexual development, prevent early epiphyseal closure, promote final height gain, mitigate psychosocial consequences
  • Most effective if started before age 6
  • Optimal age to discontinue therapy: 11 years (puberty then resumes normally)
  • Does NOT cause osteoporosis (unlike in adults)
Indication for GnRH analogue in CPP:
  • Rapid pubertal progression
  • Advanced pubertal stage (Tanner 3 or greater)
  • Rapid linear growth / significant bone age advancement
  • Psychological distress
Slowly progressive CPP: Non-therapeutic observation may be appropriate (no height loss expected).
If organic cause (CNS lesion, tumor): Treat underlying cause first.

Peripheral (GnRH-Independent) Precocious Puberty

Treat underlying cause. Additional medical options:
  • CAH: Glucocorticoid replacement (hydrocortisone)
  • McCune-Albright / Familial testotoxicosis: Aromatase inhibitors (testolactone, letrozole), anti-androgens (spironolactone, bicalutamide), ketoconazole or abiraterone (inhibitors of steroidogenesis)
  • Combination: Spironolactone + ketoconazole can normalize growth rate and bone maturation

Tanner Stages (Reference)

StageGirls (Breast)Girls (Pubic Hair)Boys (Genitalia)Boys (Pubic Hair)
1PrepubertalNo hairPrepubertalNo hair
2Breast budSparse, straightTestes 4 mL, scrotal skin changeSparse, base of penis
3Breast larger, no areolar separationDarker, curly, wider spreadLonger penis, testes growMore, darker, curly
4Areola and papilla form secondary moundAdult type, not yet spread to thighsAdult shape, smaller sizeAdult but no spread to thighs
5Mature breastAdult, spread to thighsAdultAdult, spread to thighs
Sources:
  • Roberts and Hedges' Clinical Procedures in Emergency Medicine
  • Berek & Novak's Gynecology
  • Textbook of Family Medicine, 9e
  • Park's Textbook of Preventive and Social Medicine
  • Harrison's Principles of Internal Medicine, 22E
  • Goldman-Cecil Medicine
  • Katzung's Basic and Clinical Pharmacology, 16th Edition
This is a shared conversation. Sign in to Orris to start your own chat.